Infectious Disease

Infectious Disease includes companies developing antivirals, antibiotics, vaccines, and other programs aimed at preventing or treating viral, bacterial, or fungal infections. It is a broad category that can span both commercial public health products and early-stage pipeline assets.

Why watch Infectious Disease

This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.

Latest Infectious Disease news

The latest feed items from companies currently grouped under Infectious Disease.

1. 01
   2026-09-16 21:33 EST

   ANTXAN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

   Source: AN2 Therapeutics

2. 02
   2026-09-15 12:00 EST

   SCYXSCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development

   Source: SCYNEXIS

3. 03
   2026-09-14 12:45 EST

   VIRIDogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial

   Source: Virios Therapeutics

4. 04
   2026-09-14 12:35 EST

   MBRXMoleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings

   Source: Moleculin Biotech, Inc.

5. 05
   2026-09-11 12:30 EST

   MBRXMoleculin Presentation from H.C. Wainwright Conference Now Available On-Demand

   Source: Moleculin Biotech, Inc.

6. 06
   2026-09-10 20:15 EST

   ASMBAssembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

   Source: Assembly Biosciences

7. 07
   2026-09-10 13:30 EST

   IMNNIMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

   Source: Imunon

8. 08
   2026-09-10 12:00 EST

   SCYXSCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer

   Source: SCYNEXIS

9. 09
   2026-09-09 12:30 EST

   IMNNIMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

   Source: Imunon

10. 10
    2026-09-09 11:00 EST

    COCPCocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

    Source: Cocrystal Pharma

11. 11
    2026-09-08 20:00 EST

    ASMBAssembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program

    Source: Assembly Biosciences

12. 12
    2026-09-08 11:00 EST

    AVIRAtea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

    Source: Atea

13. 13
    2026-09-03 21:05 EST

    SPROSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Source: Spero Therapeutics

14. 14
    2026-09-02 21:01 EST

    SPROSpero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

    Source: Spero Therapeutics

15. 15
    2026-09-01 12:30 EST

    SCYXSCYNEXIS to Participate in Upcoming Investor Conferences

    Source: SCYNEXIS

16. 16
    2026-09-01 11:00 EST

    ENTAEnanta Pharmaceuticals to Participate in September Investor Conferences

    Source: Enanta Pharmaceuticals

17. 17
    2026-08-31 22:00 EST

    ANTXAN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

    Source: AN2 Therapeutics

18. 18
    2026-08-27 13:01 EST

    MBRXMoleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference

    Source: Moleculin Biotech, Inc.

19. 19
    2026-08-26 12:30 EST

    IMNNIMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001

    Source: Imunon

20. 20
    2026-08-25 23:06 EST

    SCYXSCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

    Source: SCYNEXIS

Companies in Infectious Disease

31 companies tagged with Infectious Disease.

Frequently Asked Questions